Body mass index and survival of patients with lymphoma

References

• Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443–459.
   PubMed Web of Science ®Google Scholar
• Institute NC. Surveillance, epidemiology, and end results program, cancer stat facts; [cited 2020 Jun]; 2020. Available from: www.seer.cancer.gov; https://seer.cancer.gov/statfacts/
   Google Scholar
• Collaboration N. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet. 2017;390:2627–2642.
   PubMed Web of Science ®Google Scholar
• Di Angelantonio E, Bhupathiraju SN, Wormser D, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016;388(10046):776–786.
   PubMed Web of Science ®Google Scholar
• Parekh N, Chandran U, Bandera EV. Obesity in cancer survival. Annu Rev Nutr. 2012;32:311–342.
   PubMed Web of Science ®Google Scholar
• Geyer SM, Morton LM, Habermann TM, et al. Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma: a population-based study. Cancer. 2010;116(12):2993–3000.
   PubMed Web of Science ®Google Scholar
• Weiss L, Melchardt T, Egle A, et al. Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial. Ann Hematol. 2017;96:1155–1162.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Rademaker AW, Gordon LI, et al. High body mass index in elderly patients with DLBCL treated with rituximab-containing therapy compensates for negative impact of male sex. J Natl Compr Canc Netw. 2016;14:1274–1281.
   PubMed Web of Science ®Google Scholar
• Carson KR, Bartlett NL, McDonald JR, et al. Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma. J Clin Oncol. 2012;30(26):3217–3222.
   PubMed Web of Science ®Google Scholar
• Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin. 2012;62:243–274.
   PubMed Web of Science ®Google Scholar
• Cerhan JR, Link BK, Habermann TM, et al. Cohort profile: the lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. Int J Epidemiol. 2017;46:1753–1754i.
   PubMed Web of Science ®Google Scholar
• Swerdlow S, Campo E, Harris N, et al. In: Lyon F, editor. WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer; 2008.
   Google Scholar
• Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695–706.
   PubMed Web of Science ®Google Scholar
• Boyle T, Connors JM, Gascoyne RD, et al. Physical activity, obesity and survival in diffuse large B-cell and follicular lymphoma cases. Br J Haematol. 2017;178:442–447.
   PubMed Web of Science ®Google Scholar
• Hong F, Habermann TM, Gordon LI, et al. The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. Ann Oncol. 2014;25:669–674.
   PubMed Web of Science ®Google Scholar
• Simard JF, Baecklund F, Chang ET, et al. Lifestyle factors, autoimmune disease and family history in prognosis of non-Hodgkin lymphoma overall and subtypes. Int J Cancer. 2013;132(11):2659–2666.
   PubMed Web of Science ®Google Scholar
• Hosgood HD, Gunter MJ, Murphy N, et al. The relation of obesity-related hormonal and cytokine levels with multiple myeloma and non-Hodgkin lymphoma. Front Oncol. 2018;8:103.
   PubMed Web of Science ®Google Scholar
• Kane E, Skibola CF, Bracci PM, et al. Non-Hodgkin lymphoma, body mass index, and cytokine polymorphisms: a pooled analysis from the InterLymph Consortium. Cancer Epidemiol Biomarkers Prev. 2015;24:1061–1070.
   PubMed Web of Science ®Google Scholar
• Patel AV, Diver WR, Teras LR, et al. Body mass index, height and risk of lymphoid neoplasms in a large United States cohort. Leuk Lymphoma. 2013;54(6):1221–1227.
   PubMed Web of Science ®Google Scholar
• Mir MA, Maurer MJ, Ziesmer SC, et al. Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. Blood. 2015;125:992–998.
   PubMed Web of Science ®Google Scholar
• Sonbol MB, Maurer MJ, Stenson MJ, et al. Elevated soluble IL-2Ralpha, IL-8, and MIP-1beta levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma. Am J Hematol. 2014;89(12):E223–E227.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Maurer MJ, Ziesmer SC, et al. Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. Am J Hematol. 2012;87:865–869.
   PubMed Web of Science ®Google Scholar
• Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012;30(13):1553–1561.
   PubMed Web of Science ®Google Scholar
• Muller C, Murawski N, Wiesen MH, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012;119:3276–3284.
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Wolff AC, Mathijssen RH, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol. 2007;25(30):4707–4713.
   PubMed Web of Science ®Google Scholar
• Gay C, Delarue R, Milpied N, et al. Impact of doxorubicin dose capping on the outcome of DLBCL patients with elevated body surface area. Blood. 2017;129:2811–2813.
   PubMed Web of Science ®Google Scholar